Sonke, Gabe S.

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 2,870

Ribociclib as first-line therapy for HR-positive, advanced breast cancer

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 2,039

AACR Project GENIE: Powering Precision Medicine through an International Consortium

The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 1,964

Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3

Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,121

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K. L., Winer, E. P., et al. (2018) · Annals of Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 876

Overall survival with ribociclib plus fulvestrant in advanced breast cancer

Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2020) · New England Journal of Medicine

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 865

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Hart, L., Campone, M., Petrakova, K., Winer, E. P., Janni, W., et al. (2022) · New England Journal of Medicine

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 791

Effects and moderators of exercise on quality of life and physical function in patients with cancer: an individual patient data meta-analysis of 34 RCTs

Buffart, L. M., Kalter, J., Sweegers, M. G., Courneya, K. S., Newton, R. U., Aaronson, N. K., Jacobsen, P. B., May, A. M., Galvão, D. A., Chinapaw, M. J., et al. (2017) · Cancer Treatment Reviews

Cancer survivorship and carePhysical Activity and Health

Cited by 595

Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial

DiSilvestro, P., Banerjee, S., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., et al. (2023) · Journal of Clinical Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 511

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

Slamon, D. J., Neven, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., Petrakova, K., Valeria Bianchi, G., Martín, M., Nusch, A., et al. (2021) · Annals of Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 281

Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data

Sweegers, M. G., Altenburg, T. M., Brug, J., May, A. M., van Vulpen, J. K., Aaronson, N. K., Arbane, G., Bohus, M., Courneya, K. S., Daley, A. J., et al. (2019) · British Journal of Sports Medicine

Cancer survivorship and careCardiovascular and exercise physiology

Cited by 109

Targeting exercise interventions to patients with cancer in need: an individual patient data meta-analysis

Buffart, L. M., Sweegers, M. G., May, A. M., Chinapaw, M. J., van Vulpen, J. K., Newton, R. U., Galvão, D. A., Aaronson, N. K., Stuiver, M. M., Jacobsen, P. B., et al. (2018) · JNCI: Journal of the National Cancer Institute

Cancer survivorship and careCardiovascular and exercise physiology

Cited by 103

Why do patients choose (not) to participate in an exercise trial during adjuvant chemotherapy for breast cancer?

van Waart, H., van Harten, W. H., Buffart, L. M., Sonke, G. S., Stuiver, M. M., & Aaronson, N. K. (2016) · Psycho-Oncology

Cancer survivorship and carePhysical Activity and Health

Cited by 95

Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).

Sonke, G. S., Van Ommen - Nijhof, A., Wortelboer, N., van der Noort, V., Swinkels, A. C. P., Blommestein, H. M., Beeker, A., Beelen, K., Hamming, L. C., Heijns, J. B., et al. (2023) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 88

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.

Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A., et al. (2023) · Breast Cancer Research

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 83

Cost–utility and cost-effectiveness of physical exercise during adjuvant chemotherapy

van Waart, H., van Dongen, J. M., van Harten, W. H., Stuiver, M. M., Huijsmans, R., Hellendoorn-van Vreeswijk, J. A. J. H., Sonke, G. S., & Aaronson, N. K. (2018) · The European Journal of Health Economics

Health Systems, Economic Evaluations, Quality of LifeCancer survivorship and care

Cited by 56

BRCA1 -Mutated Estrogen Receptor–Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency

Lips, E. H., Debipersad, R. D., Scheerman, C. E., Mulder, L., Sonke, G. S., van der Kolk, L. E., Wesseling, J., Hogervorst, F. B. L., & Nederlof, P. M. (2017) · Clinical Cancer Research

BRCA gene mutations in cancerPARP inhibition in cancer therapy

Cited by 22

Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels

Jongbloed, E. M., Jansen, M. P. H. M., de Weerd, V., Helmijr, J. A., Beaufort, C. M., Reinders, M. J. T., van Marion, R., van IJcken, W. F. J., Sonke, G. S., Konings, I. R., et al. (2023) · Scientific Reports

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 6